Introduction {#s1}
============

Lung cancer is one of the highest incidences of malignant tumors worldwide derived from the epithelium, mucosa, or gland of the bronchus, and the incidence of lung cancer in China in recent years is also increasing ([@CIT0001]). Approximately 80--85% of all lung cancer cases are non-small cell lung cancer ([@CIT0002]). Many efforts have been made to improve the discovery of lung cancer. However, due to the lack of typical early clinical symptoms and signs, the early diagnosis rate of lung cancer is low. Most patients have developed to the middle and advanced stage in diagnosis and, therefore, missed the best time for patients with surgical resection ([@CIT0003]). Recently, radiotherapy, chemotherapy and targeted drug therapy are the first choices for killing tumor cells and prolonging the survival time of the patients. The key signaling pathways contributed to the lung cancer cell growth and metastasis have been confirmed as we have made great progress in our understanding of tumor biology ([@CIT0004]). The dominant oncogenes and tumor suppressor genes involved in the course of lung cancer have received continuous attention and their core roles and basic contributions to the behavior of tumor cells became clear ([@CIT0005]).

Rho GTPase-activating protein 24 (ARHGAP24) belongs to the small GTPase family that can hydrolyze the active guanosine triphosphate (GTP) into inactive GDP and negatively regulate Rho family GTPases such as RhoA and Rac1 and, therefore, is strongly associated with the onset and progression of cancer ([@CIT0006]). ARHGAP24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis ([@CIT0009]). DLC1, a new member of GAP family, has been found to possess RhoGAP activity and associates with the apoptosis and proliferation of breast cancer and Burkitt's lymphoma cells ([@CIT0010],[@CIT0011]). ARHGAP21 is highly expressed in head and neck squamous cell carcinoma ([@CIT0012]), and ARHGAP21 knockdown inhibited the proliferation of prostate adenocarcinoma PC3 cells ([@CIT0013]). Downregulated ARHGAP24 was observed in renal cancer, and ARHGAP24 overexpression-induced cell apoptosis and cell cycle arrest, along with restrained cell proliferation of renal cancer ([@CIT0014],[@CIT0015]). ARHGAP24 overexpression significantly reduced growth of tumors from breast cancer HCC1954 and MDA-MB-231 cells implantation ([@CIT0016]). In addition, ARHGAP24 promoted sorafenib-induced decrease of the viability, migration and invasion in breast cancer cells ([@CIT0017]). Our previous study demonstrated that ARHGAP24 silencing promoted lung cancer cell migration and invasion through activating β-catenin signaling ([@CIT0018]). However, it is rarely known about the functional role of ARHGAP24 in the regulation of cell cycle and apoptosis of lung cancer and the underlying mechanism involved except for its downregulation in lung adenocarcinoma ([@CIT0019]).

STATs are a class of DNA-binding proteins that form part of the JAK-STAT signaling cascade, including STAT1--STAT6, which are of great importance in cellular immune response, cell differentiation, apoptosis and proliferation ([@CIT0020],[@CIT0021]). STAT6 has been shown to act as a co-activator of transcription factors. Inhibition of interleukin 13-induced STAT6 activation resulted in decreased Lewis lung cancer cell invasion and migration *in vitro* and tumor formation *in vivo* ([@CIT0022]). STAT6-specific small interfering RNA inhibited cell viability, colony formation and induced apoptosis of lung cancer cells by downregulating the Bcl-xL expression through binding to the Bcl-xL promoter ([@CIT0023]). In contrast, STAT6 overexpression inhibited G~1~/S transition through increasing p27 messenger RNA (mRNA) levels in breast cancer cells by binding to the p27 promoter ([@CIT0024]). Moreover, bioinformatics analysis predicted that STAT6 can bind to the promoter of WWP2, which was a target of micro RNA 140 that downregulated in lung cancer and suppressed cell growth ([@CIT0025]), suggesting that STAT6/WWP2 may participate in the development of lung cancer. There is a general view around that Rho GTPases involve in the tumorigenesis through mediating not only the Rho pathway ([@CIT0013]) but also the STATs pathway ([@CIT0026],[@CIT0027]). These researches prompted us to explore the functional role of ARHGAP24 in the regulation of the STAT6-WWP2 pathway in lung cancer.

The purpose of the present study is to evaluate the molecular mechanisms underlying ARHGAP24-mediated lung cancer cell growth and, hence, we examined the ARHGAP24 expression in lung cancer and its effects on cell proliferation, cell cycle and apoptosis in lung cancer cells. In the present study, we found that ARHGAP24 acts as a tumor suppressor inducing apoptosis and cell cycle blockage and inhibiting the cell proliferation of lung cancer. Inhibiting STAT6 signaling reserved ARHGAP24 silencing-induced cell proliferation and WWP2 expression. WWP2 overexpression promoted cell cycle progression and cell proliferation through ubiquitination of p27 in lung cancer. Therefore, ARHGAP24 regulates the cell growth of lung cancer via a STAT6-WWP2-p27 axis.

Materials and methods {#s2}
=====================

Clinical samples {#s3}
----------------

The lung cancer tissues (*n* = 30) and corresponding normal (adjacent non-tumor) lung tissues (*n* = 30) were collected from patients with lung cancer in Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine recruited from March 2014 to October 2017. All of the patients provided signed informed consent. The medical ethics committee of Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine approved the present retrieval method of cancer specimens.

Bioinformatics analysis {#s4}
-----------------------

RNA-sequencing data set of lung cancer cohort was downloaded from The Cancer Genome Atlas (TCGA; <https://tcga-data.nci.nih.gov/tcga/>) and analyzed by gene set enrichment analysis (GSEA) software version 2.0 as described previously ([@CIT0028]).

Cell culture {#s5}
------------

A549, NCI-H1299, NCI-H292, NCI-H1975 and NCI-H460 human lung cancer cell lines obtained from American Type Culture Collection (ATCC; Manassas, VA) were cultured with RPMI-1640 medium (Hyclone) containing 10% fetal bovine serum (FBS; Gibco) and 1% antibiotic (mixtures of penicillin and streptomycin; Solarbio) in a 37°C, 5% CO~2~ incubator (Thermo). The old medium was replaced by fresh medium depending on the growth of cells during the period of culture.

Cell line authentication {#s6}
------------------------

A549, NCI-H1299, NCI-H292, NCI-H1975 and NCI-H460 human lung cancer cell lines were obtained from the ATCC in April 2017. All cell lines were authenticated by short tandem repeat PCR profiling. No cross contamination of other human cells was observed. The last time the cell lines were tested was in March 2018.

Cell transduction {#s7}
-----------------

ARHGAP24 (NM_001025616.2) interference sequences (position 727--749: 5'-GATCGGATGACAGCAAATC-3'; position 768--788: 5'-GCAAGCACCCAGAATGATATG-3' position; 4023--4043: 5'-GGAGAACAGTTCTTCACAATA-3') were cloned into pLKO.1 plasmid to knockdown ARHGAP24 expression. The coding sequences of ARHGAP24 or WWP2 were, respectively, synthesized using the primers containing the restriction enzyme cutting sites of *Bam*HI and *Eco*RI (ARHGAP24 Forward: 5'-GCGAATTCATGGAGGAGAACAATGACT-3' and Reverse: 5'-CGGGATCCCTGAATCCATATTGTGTTT-3'; WWP2 Forward: 5'-GCGAATTCATGGCATCTGCCAGCTCTAGCCGGG-3'; Reverse: 5'-CGGGATCCTTACTCCTGTCCAAAGCCCTCGGTC-3') and integrated into pLVX-Puro plasmid to elevate ARHGAP24 and WWP2 expression. Recombinant plasmids along with the psPAX2 and pMD2G packaging plasmids were co-transfected into 293T cells using lipofectamine 2000 (Invitrogen). NCI-H1975 cells were transduced with the pLKO.1-ARHGAP24-shRNA, and NCI-H460 and A549 cells were transduced with the pLVX-Puro-ARHGAP24 or pLVX-Puro-WWP2. Cells with pLKO.1-scramble shRNA or blank pLVX-Puro transduction were used as negative control.

CCK-8 assay {#s8}
-----------

CCK-8 assay was performed using a Cell Proliferation and Cytotoxicity Assay Kit (SAB, CP002). Briefly, 100 μl of cell suspension containing 1 × 10^4^ lung cancer cells was added to each well of the 96-well plates. NCI-H1975 cells were transduced with pLKO.1-ARHGAP24-shRNA, and NCI-H460 and A549 cells were transduced with pLVX-Puro-ARHGAP24 or pLVX-Puro-WWP2. After incubation for 24, 48 and 72 h, 10 μl of CCK-8 solution was added to each well. Cell proliferation was evaluated using the absorbance at 450 nm.

Cell cycle analysis {#s9}
-------------------

In the 6-well plates, 3 × 10^5^ lung cancer cells were grown and incubated for 24 h. NCI-H1975 cells were transduced with pLKO.1-ARHGAP24-shRNA, and NCI-H460 and A549 cells were transduced with pLVX-Puro-ARHGAP24 or pLVX-Puro-WWP2. At 48 h after lentivirus transduction, the cells were trypsinized and washed with precooled phosphate-buffered saline (PBS). Three hundred microliters of PBS contained 10% FBS and 700 μl of −20°C precooled absolute ethyl alcohol was successively added for cell fixation. After incubated at 4°C for 24 h, cell suspension was centrifuged and washed with precooled PBS again. Hundred microliters of ribonuclease A (1 mg/ml) was added for cell resuspension. After being incubated in dark for 30 min, the cells were stained with 400 μl of propidium iodide (PI, 50 μg/ml) for 10 min. Cell cycle distribution was analyzed with a flow cytometer (Becton-Dickinson FACS Calibur, San Joes, CA).

Cell apoptosis assay {#s10}
--------------------

Cells were seeded in six-well plate (5 × 10^5^/well) and grew adherently until reaching 50% of confluence. Collected A549 and NCI-H460 cells were transduced with the pLVX-Puro-ARHGAP24 vector. At 48 h after lentivirus transduction, cell apoptosis was assessed using flow cytometry. Briefly, cells were maintained with 5 μl fluorescein isothiocyanate-labeled recombinant annexinV (Annexin V-FITC) for 15 min in the dark at 4°C, followed by 5 μl PI for another 15 min.

Real-time PCR analysis {#s11}
----------------------

We applied real-time PCR to detect the mRNA levels of ARHGAP24, WWP2 and p27. First, extraction of total RNA from lung cancer tissues and cell lines was achieved by trizol (Invitrogen). Then after the extracted RNA quantified, whether it degraded was detected by 1% agarose gel electrophoresis. Subsequently, reverse transcriptase kit (Fermentas) was used to reverse the isolated RNA into complementary DNA. Real-time PCR reactions were carried out by SYBR Green PCR kit (Thermo), and ABI Prism 7300 SDS Software was applied to analyze the mRNA level of ARHGAP24, WWP2 and p27 normalizing to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), using the 2^△△CT^ method. The following were all primer sequences: ARHGAP24, 5'-AACTCCTGTCGCTCTTCTACC-3' and 5'-GCTGTTGCCCACAAATGTCTC-3'; WWP2, 5'-AGGCTAAAGAGGG CTGGAGT-3' and 5'-GCTTTGCGGACACCACTTTC-3'; *p27*, 5'-CTCTGCTCTCA CCTCATC-3' and 5'-GCCACAACTCCTCCAATC-3'; GAPDH, 5'-CACCCACT CCTCCACCTTTG-3' and 5'-CCACCACCCTGTTGCTGTAG-3'.

Western blotting {#s12}
----------------

At 48 h after lentivirus transduction, cells were collected for analyzing ARHGAP24, WWP2 and p27 levels; at 24 h after lentivirus transduction, cells were collected for analyzing RhoA and Rac1 activity; and at 6 h after lentivirus transduction, cells were collected for analyzing p-STAT6 and STAT6 levels. Total protein was extracted using a total protein extraction buffer (Beyotime, China). An equal amount of protein was incubated with glutathione S-transferase-rhotekin (Upstate Biotechnologies, Lake Placid, NY) for 45 min at 4°C to collect the active form of RhoA (GTP-RhoA) or Rac1 (GTP-Rac1). Ten percent sodium dodecyl sulfate polyacrylamide gel was prepared to isolate the proteins. After being transferred to nitrocellulose membrane, the bands were blocked with 5% non-fat milk. The blots were incubated with primary and second antibodies, which were diluted to appropriate concentrations and added to the protein bands, respectively. The antibodies and reagents used were as follows: ARHGAP24 (Abcam, ab203874, 1:500); WWP2 (Abcam, ab103527, 1:2000); p27 (Abcam, ab193379, 1:5000); STAT6 (Abcam, ab32520, 1:1000); p-STAT6 (Abcam, ab28829, 1:500); RhoA (Santa Cruz Biotechnology, sc-418, 1:1000); Rac1 (Santa Cruz Biotechnology, sc-217, 1:1000); GAPDH (Cell Signaling Technology, \#5174, 1:2000); horseradish peroxidase (HRP) labeled Goat Anti-Rabbit IgG (Beyotime, A0208, 1:1000); HRP-labeled Donkey Anti-Goat IgG (Beyotime, A0181, 1:1000); HRP-labeled Goat Anti-Mouse IgG (Beyotime, A0216, 1:1000). The results were used to visualize the proteins by the enhanced chemi-luminescence reagents (Thermo Scientific).

Co-immunoprecipitation and ubiquitination *in vitro* {#s13}
----------------------------------------------------

Co-immunoprecipitation (Co-IP) was performed as described previously ([@CIT0029]). Briefly, cold PBS was used to wash the cells for three times, and the cells were scraped into lysis buffer containing complete protease inhibitors and centrifuged at 14 000 × *g* for 20 min at 4°C. The supernatants were incubated with normal IgG or anti-p27 antibody, and the immunocomplexes were then associated with protein A-sepharose. Anti-WWP2 (1:500), anti-p27 (1:500) and anti-ubiquitin (1:500) antibody (Cell Signaling Technology, Danvers, MA) were used for western blot analysis.

Animal experiments {#s14}
------------------

A total of 4 × 10^6^ A549 cells transduced with pLVX-Puro-ARHGAP24 or blank pLVX-Puro vector were trypsinized, resuspended in PBS and then injected subcutaneously into the right armpit of BALB/c male nude mice (4--5-week-old; six per group). Mice were killed at 33 days after the injection, and the cell apoptosis was monitored by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining as described previously ([@CIT0030]). Animal experiments were performed according to the legal requirements and approved by the Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine institutional ethical committee.

Statistical analysis {#s15}
--------------------

Date was present as mean value ± standard deviation. GraphPad Prism 6 software was used for statistical analysis. Cells were seeded in triplicates for each group and the experiment was independently repeated thrice. One-way analysis of variance and unpaired *t*-test were applied for the comparison of mean values. *P* \< 0.05 was regarded as statistically significant.

Results {#s16}
=======

ARHGAP24 downregulation is observed in lung cancer tissues, and ARHGAP24 overexpression suppresses lung cancer cell proliferation {#s17}
---------------------------------------------------------------------------------------------------------------------------------

*ARHGAP24* mRNA expression in normal lung tissues and lung cancer tissues in TCGA cohort analyzed by bioinformatics analysis showed that *ARHGAP24* was downexpressed in lung cancer tissues (*n* = 488) compared with normal lung tissues (*n* = 58) ([Figure 1A](#F1){ref-type="fig"}). Moreover, real-time PCR analysis showed that *ARHGAP24* was downexpressed in lung cancer tissues (*n* = 30) compared with the corresponding adjacent-normal lung tissues (*n* = 30) in independent hospital cohort ([Figure 1B](#F1){ref-type="fig"}). Similar to the ARHGAP24 mRNA expression pattern, western blotting analysis also demonstrated decreased ARHGAP24 protein expression in lung cancer tissues (*n* = 8) compared with the adjacent-normal lung tissues (*n* = 8) ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}, available at *Carcinogenesis* Online). Furthermore, the expression of ARHGAP24 in lung cancer cell lines was also measured. As shown in [Figure 1C](#F1){ref-type="fig"}, A549 and NCI-H460 cells showed the lowest ARHGAP24 protein levels, and NCI-H1975 cells demonstrated the highest ARHGAP24 protein expression compared with other lung cancer cell lines.

![ARHGAP24 expression and its role in cell proliferation of lung cancer. ARHGAP24 expression levels in lung cancer were measured by bioinformatics (**A**), real-time PCR (**B**) and western blot analysis (**C**). After A549 and NCI-H460 cells were transduced with pLVX-Puro-ARHGAP24 or blank pLVX-Puro vector, ARHGAP24 expression and cell proliferation were measured by real-time PCR (**D, G**), western blot (**E, H**) and CCK-8 analysis (**F, I**). \*\**P* \< 0.01 compared with N or vector group. N: adjacent-normal lung tissues. T: lung cancer tissues.](bgz144f0001){#F1}

To investigate the function of ARHGAP24 in lung cancer tumorigenesis, A549 and NCI-H460 cells were transduced with recombinant pLVX-Puro-ARHGAP24 vector to upregulation of ARHGAP24 and the cell proliferation was measured subsequently. Our results found that upregulation of ARHGAP24 in A549 cells significantly increased the ARHGAP24 mRNA and protein levels by 53.9-fold and 1.36-fold ([Figure 1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}) and inhibited A549 cell proliferation by 38.7% and 44.4% at 48 and 72 h, respectively ([Figure 1F](#F1){ref-type="fig"}), compared with blank pLVX-Puro vector transduction, whereas upregulation of ARHGAP24 in NCI-H460 cells significantly increased the ARHGAP24 mRNA and protein levels by 61.3-fold and 2.56-fold ([Figure 1G](#F1){ref-type="fig"} and [H](#F1){ref-type="fig"}) and inhibited NCI-H460 cell proliferation by 37.7% and 42.1% at 48 and 72 h, respectively ([Figure 1I](#F1){ref-type="fig"}), compared with blank pLVX-Puro vector transduction.

ARHGAP24 overexpression induces cell cycle arrest at G~0~--G~1~ phase and apoptosis of A549 and NCI-H460 cells {#s18}
--------------------------------------------------------------------------------------------------------------

Based on the effect of ARHGAP24 on the cell proliferation of lung cancer, the cell cycle progression and apoptosis of A549 and NCI-H460 cells after pLVX-Puro-ARHGAP24 transduction were also measured. Upregulation of ARHGAP24 in A549 and NCI-H460 cells significantly induced cell cycle arrest at G~0~--G~1~ phase, evidenced by the increased cell number of G~0~--G~1~ phase and decreased cell number of S and G~2~--M phases compared with pLVX-Puro vector ([Figure 2A--D](#F2){ref-type="fig"}). Meanwhile, upregulation of ARHGAP24 in A549 and NCI-H460 cells significantly increased cell apoptosis by 3.97-fold and 3.96-fold compared with pLVX-Puro vector, respectively ([Figure 2E--H](#F2){ref-type="fig"}). These results suggest that ARHGAP24 inhibits lung cancer tumorigenesis through inhibiting lung cancer cell growth.

![ARHGAP24 overexpression induces cell cycle arrest and apoptosis of A549 and NCI-H460 cells. After A549 and NCI-H460 cells were transduced with pLVX-Puro-ARHGAP24 or blank pLVX-Puro vector, cell cycle (**A--D**) and cell apoptosis (**E--H**) were measured by flow cytometry. \*\**P* \< 0.01 compared with vector group.](bgz144f0002){#F2}

Correlation of ARHGAP24 with WWP2, p27 and p-STAT6 expression in lung cancer {#s19}
----------------------------------------------------------------------------

Our GSEA analysis from lung cancer TCGA data set found that ARHGAP24 expression was negative correlation with KEGG Ubiquitin-mediated proteolysis and Reactome Cell cycle ([Figure 3A](#F3){ref-type="fig"}). WWP2, which encodes a member of the Nedd4 family of E3 ligases playing an important role in protein ubiquitination, and CDKN1B (p27), which encodes a cyclin-dependent kinase inhibitor controlling the cell cycle progression at G~1~, were further examined in lung cancer tissues, respectively. We found that WWP2 expression was higher, but p27 expression was lower in lung cancer tissues compared with normal lung tissues in the independent hospital corhort ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}, available at *Carcinogenesis* Online).

![Correlation of ARHGAP24 with WWP2, p27 and p-STAT6 expression in lung cancer. TCGA lung cancer cohort was analyzed by GSEA. (**A**) Enrichment plots of gene expression signatures for KEGG Ubiquitin-mediated proteolysis and Reactome Cell cycle according to ARHGAP24 expression levels. After A549 and NCI-H460 cells were transduced with pLVX-Puro-ARHGAP24 or blank pLVX-Puro vector, the (**B**) expression of WWP2 and P27, (**C**) activity of RhoA and Rac1 and (**D**) levels of p-STAT6 and STAT6 were measured by western blot analysis. \*\**P* \< 0.01 compared with vector group.](bgz144f0003){#F3}

Moreover, ARHGAP24 overexpression in A549 and NCI-H460 cells showed significant decrease in WWP2 expression and increase in p27 expression compared with blank pLVX-Puro vector ([Figure 3B](#F3){ref-type="fig"} and [Supplementary Figure S1B](#sup1){ref-type="supplementary-material"} and [C](#sup1){ref-type="supplementary-material"}, available at *Carcinogenesis* Online). ARHGAP24 mediates reciprocal processes or specifically inactivates Rac downstream of Rho ([@CIT0031]). Here, the decreased RhoA and Rac1 activity in A549 and NCI-H460 cells were also observed with ARHGAP24 overexpression ([Figure 3C](#F3){ref-type="fig"}). Rho family GTPases have been implicated in controlling cell proliferation and gene expression through regulating STATs transcriptional activity ([@CIT0026],[@CIT0027]). These observations prompted us to examine the role of ARHGAP24 in the regulation of STAT6, which was predicted to bind to the WWP2 promoter using the JASPAR database (<http://jaspardev.genereg.net/>) ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}, available at *Carcinogenesis* Online). As shown in [Figure 3D](#F3){ref-type="fig"}, ARHGAP24 overexpression in A549 and NCI-H460 cells significantly inhibited the activation of STAT6 signaling. These findings suggest that ARHGAP24 may regulate lung cancer cell growth through STAT6/WWP2 signaling.

ARHGAP24 overexpression inhibits tumor growth in nude mice {#s20}
----------------------------------------------------------

To determine whether ARHGAP24 overexpression in lung cancer cells could inhibit tumor growth *in vivo*, A549 cells stable transduced with pLVX-Puro-ARHGAP24 or blank pLVX-Puro vector were injected subcutaneously into the nude mice. Mice were killed 33 days after injection, with average tumor weights of 1.98 ± 0.24 g and 0.44 ± 0.14 g in blank pLVX-Puro- and pLVX-Puro-ARHGAP24-treated mice, respectively ([Figure 4A](#F4){ref-type="fig"}). Moreover, pLVX-Puro-ARHGAP24-treated tumors showed decreased growth and increased cell apoptosis compared with the blank pLVX-Puro vector treated tumors in nude mice ([Figure 4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}). The protein expression of ARHGAP24 and p27 was significantly increased, but that of WWP2 and p-STAT6 as well as the activity of RhoA and Rac1 were decreased after ARHGAP24 overexpression in xenograft from the nude mice ([Figure 4D--G](#F4){ref-type="fig"}).

![ARHGAP24 overexpression inhibits tumor growth of lung cancer in nude mice. After A549 cells transduced with pLVX-Puro-ARHGAP24 or blank pLVX-Puro vector were injected subcutaneously into the nude mice, the tumor weight (**A**), volume (**B**) and cell apoptosis (**C**) were measured as described in Materials and methods. The expression of ARHGAP24, WWP2, P27, p-STAT6 and STAT6, as well as the activity of RhoA and Rac1, were measured by western blot analysis (**D--G**). Scale bars: 100 μm. \*\**P* \< 0.01 compared with vector group.](bgz144f0004){#F4}

ARHGAP24 knockdown promotes cell proliferation and WWP2 expression in NCI-H1975 cells through activating STAT6 signaling {#s21}
------------------------------------------------------------------------------------------------------------------------

To further confirm the effects of ARHGAP24 on cell growth in lung cancer cells, NCI-H1975 cells were transduced with three pLKO.1-ARHGAP24-shRNAs or pLKO.1-scramble shRNA. As shown in [Figure 5A](#F5){ref-type="fig"} and [B](#F5){ref-type="fig"}, three pLKO.1-ARHGAP24-shRNAs transduction in NCI-H1975 cells markedly reduced the ARHGAP24 protein and mRNA expression, with the lower ARHGAP24 expression observed in NCI-H1975 cells with pLKO.1-ARHGAP24-shRNA-1 and pLKO.1-ARHGAP24-shRNA-2 transduction. These two pLKO.1-ARHGAP24-shRNAs were, therefore, used for subsequent experiments. CCK-8 analysis demonstrated that pLKO.1-ARHGAP24-shRNA transduction promoted cell proliferation and inhibited cell cycle blockage compared with pLKO.1-scramble shRNA transduction ([Figure 5C](#F5){ref-type="fig"} and [D](#F5){ref-type="fig"}). Meanwhile, ARHGAP24 knockdown also promoted WWP2 expression, STAT6 activation and activity of RhoA and Rac1 but inhibited p27 expression ([Figure 5E](#F5){ref-type="fig"} and [Supplementary Figure S1D](#sup1){ref-type="supplementary-material"}, available at *Carcinogenesis* Online).

![ARHGAP24 knockdown promotes cell growth in NCI-H1975 cells through activating STAT6 signaling. After NCI-H1975 cells were transduced with pLKO.1-ARHGAP24-shRNAs or pLKO.1-scramble shRNA, the cell proliferation, cell cycle, expression of ARHGAP24, WWP2, P27, p-STAT6 and STAT6, and activity of RhoA and Rac1 were measured by CCK-8 (**C**), flow cytometry (D), real-time PCR (A) and western blot (B, E) analysis. After NCI-H1975 cells were treated with 25 nM AS1517499 for 2 h prior to transduce with pLKO.1-ARHGAP24-shRNA-1 or pLKO.1-scramble shRNA, the cell proliferation (**F**) and WWP2 expression (**G**) were measured by CCK-8, real-time PCR and western blot analysis. \*\**P* \< 0.01 compared with scramble shRNA group. ^\#\#^*P* \< 0.01 compared with ARHGAP24-shRNA-1 group.](bgz144f0005){#F5}

To investigate the involvement of STAT6 signaling in ARHGAP24-mediated lung cancer cell growth as well as the WWP2 expression, NCI-H1975 cells were treated with 25 nM AS1517499, a novel STAT6 inhibitor, for 2 h prior to pLKO.1-ARHGAP24-shRNA-1 or pLKO.1-scramble shRNA transduction. Our data showed that AS1517499 treatment significantly inhibited ARHGAP24 knockdown-induced cell proliferation and WWP2 expression in NCI-H1975 cells ([Figure 5F](#F5){ref-type="fig"} and [G](#F5){ref-type="fig"}). These data suggest that ARHGAP24 regulates lung cancer cell growth through STAT6/WWP2 signaling pathway.

WWP2 overexpression promotes cell proliferation and cell cycle progression in A549 cells {#s22}
----------------------------------------------------------------------------------------

To confirm the involvement of WWP2/p27 in lung cancer cell cycle progression and proliferation *in vitro*, A549 cells were transduced with pLVX-Puro-WWP2 in the absence or presence of pLVX-Puro-ARHGAP24 ([Figure 6A](#F6){ref-type="fig"}). In addition, upregulation of WWP2 promoted cell proliferation and inhibited cell cycle arrest at G~0~--G~1~ phase and p27 expression, which were corrected by ARHGAP24 overexpression ([Figure 6B--D](#F6){ref-type="fig"}). However, the p27 mRNA level was not changed after WWP2 overexpression, suggesting the posttranscriptional regulation of p27 by WWP2. Indeed, Co-IP assay demonstrated that WWP2 interacted with p27, and WWP2 overexpression significantly promoted the ubiquitination of p27 in A549 cells ([Figure 6E](#F6){ref-type="fig"}). These results suggest that WWP2 may regulate lung cancer cell cycle progression through ubiquitination of p27.

![WWP2 overexpression promotes cell proliferation and cell cycle progression in A549 cells. After A549 cells were transduced with pLVX-Puro-WWP2 in the absence or presence of pLVX-Puro-ARHGAP24, WWP2 and ARHGAP24 expression (**A**), cell proliferation (**B**), cell cycle (**C**) and p27 expression (**D**) were measured by CCK-8, flow cytometry, real-time PCR and western blot analysis. (**E**) Co-IP showed that WWP2 interacted with p27 in A549 cells, and p27 was immunoprecipitated and immunoblotted in A549 cells with pLVX-Puro-WWP2 or blank pLVX-Puro transduction. (**F**) WWP2 and P27 mRNA expression levels in lung cancer tissues were measured by real-time PCR. (**G**) Pearson correlation scatter plots in lung cancer tissues (*n* = 30). (**H**) Schematic representation of ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer through inactivating STAT6 signaling, leading to inhibition of WWP2-dependent ubiquitination of P27. \*\**P* \< 0.01 compared with vector group. ^\#\#^*P* \< 0.01 compared with WWP2 group.](bgz144f0006){#F6}

Expression of WWP2 and p27 in lung cancer tissues and its correlation with ARHGAP24 {#s23}
-----------------------------------------------------------------------------------

Real-time PCR analysis showed that WWP2 mRNA levels were upexpressed and p27 mRNA levels were downexpressed in lung cancer tissues (*n* = 30) compared with the corresponding adjacent-normal lung tissues (*n* = 30) in independent hospital cohort ([Figure 6F](#F6){ref-type="fig"}). Furthermore, Pearson correlation analysis demonstrated that ARHGAP24 mRNA expression was negatively correlated with the mRNA expression of WWP2 in lung cancer tissues (*n* = 30), whereas there was a positive correlation with p27 mRNA expression ([Figure 6G](#F6){ref-type="fig"}). These data further supported the findings in lung cancer cell lines.

Discussion {#s24}
==========

Rho family GTPase is a widely existing and evolutionary conservative family of GTP-binding proteins, driven by signaling from RhoGAPs, and its abnormality results in the dysregulated cell growth and motility in cancer progression ([@CIT0032]). In addition, ARHGAP24 should be determined to clarify the functional role of this subfamily of RhoGAPs. In this study, decreased ARHGAP24 expression was found in lung cancer tissues compared with normal lung tissues. ARHGAP24 overexpression inhibited cell growth of lung cancer *in vitro* and *in vivo*, evidenced by decreased cell proliferation, arrested cell cycle and increased cell apoptosis through STAT6 signaling. WWP2 overexpression promoted lung cancer cell growth through ubiquitination of p27. These data suggest that ARHGAP24 regulates the cell proliferation, apoptosis and cell cycle progression of lung cancer via a STAT6-WWP2-p27 axis ([Figure 6H](#F6){ref-type="fig"}).

Previous study has shown that ARHGAP24 expression was lower in renal cancer tissues, and ARHGAP24 upregulation inhibited cell growth, evidenced by the apoptosis and blockage of cell cycle at the G~0~--G~1~ phase *in vitro* and tumor growth in nude mice *in vivo* ([@CIT0014]). Additionally, ARHGAP24 overexpression significantly reduced growth of tumors from breast cancer cells implantation ([@CIT0016]). These findings were in consistence with the effects of ARHGAP24 in lung cancer cells. Our GSEA analysis showed that ARHGAP24 expression is negative correlation with KEGG Ubiquitin-mediated proteolysis and Reactome Cell cycle, in which WWP2 and p27 were found to be, respectively, negative and positive correlation with ARHGAP24 expression in lung cancer, suggesting the involvement of WWP2 and p27 in ARHGAP24-induced cell growth in lung cancer.

WWP2, an E3 ubiquitin ligase, is proposed to be an oncogene contributing to tumorigenesis by participating in the protein degradation, transcriptional regulation, cell proliferation and apoptosis. WWP2 was highly expressed in human lung adenocarcinoma cells, and WWP2 knockdown suppressed cell proliferation and induced cell apoptosis and G~0~--G~1~ cell cycle arrest in lung and live cancer cells ([@CIT0033],[@CIT0034]) and, thereby, may be a useful therapeutic target. In the present study, WWP2 overexpression in lung cancer cells also increased cell proliferation and inhibited cell cycle arrest, along with decreased p27 expression, which were reversed by ARHGAP24 overexpression. So far, p27 has been identified to be a substrate of WWP1 ([@CIT0035]) and we, therefore, assumed that WWP2 may also cause degradation of p27. Our Co-IP and ubiquitination analysis demonstrated that WWP2 interacted with p27, and WWP2 overexpression significantly promoted the ubiquitination of p27. These data suggested that the cell cycle transition from the G~0~/G~1~ phase to the S phase in lung cancer cells might be regulated by WWP2 through ubiquitination of P27. Meanwhile, other studies have previously showed that inhibiting WWP2-induced ubiquitination and degradation of the transcription factor Oct4 promoted tumorigenicity of hepatocellular carcinoma cells in NOD/SCID mice ([@CIT0036]), and WWP2 serves as a tumor suppressor leading to cell cycle arrest through ubiquitination of the Notch3 signaling in ovarian cancer ([@CIT0037]). Our bioinformatics analysis demonstrated that WWP2, which acts as an E3 ubiquitin ligase interacting with ARHGAP24 and may induce ubiquitination of ARHGAP24, was predicted by the UbiBrowser database (data not shown), which was consistent with the findings that WWP2 overexpression significantly inhibited the ARHGAP24 expression, suggesting a feedback loop between ARHGAP24 and WWP2 existed in lung cancer. However, the interaction between ARHGAP24 and WWP2 and the degradation of ARHGAP24 induced by WWP2 need further investigation.

Rho family GTPases have been implicated in controlling cell proliferation and gene expression through regulating STATs transcriptional activity ([@CIT0026],[@CIT0027]). ARHGAP24 negatively correlated with the activity of RhoA and Rac1 in lung cancer cells, which was in line with the previous studies ([@CIT0008],[@CIT0009]). Previous studies have reported that RhoA and Rac1 can activate STAT6 signaling pathway ([@CIT0038],[@CIT0039]). These observations prompted us to examine the role of ARHGAP24 in the regulation of STAT6, which was predicted to bind to the WWP2 promoter. Our data showed that ARHGAP24 overexpression inhibited the phosphorylation of STAT6, and blockage of STAT6 signaling significantly inhibited ARHGAP24 silencing-induced cell proliferation and WWP2 expression in lung cancer cells, indicating that ARHGAP24 may inhibit lung cancer cell growth via the inactivation of STAT6 signaling through inhibiting RhoA or Rac1 activity. These findings were in line with the functional role of STAT6 signaling in lung cancer in other studies ([@CIT0022],[@CIT0023]).

In conclusion, our results for the first time demonstrated the important role of ARHGAP24 in lung cancer cell proliferation, cell cycle progression and apoptosis. ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer through inactivating STAT6 signaling, leading to inhibition of WWP2-dependent ubiquitination of P27. These studies suggest that the STAT6-WWP2-P27 axis may represent a potential therapeutic target for treatment of human lung cancer.

 {#s25}

Funding: National Natural Science Foundation of China (81602418 and 81572248).

*Conflict of interest*: The authors declare that they have no competing interests.

Supplementary Material
======================

###### 

Click here for additional data file.

ARHGAP24

:   Rho GTPase-activating protein 24

ATCC

:   American Type Culture Collection

Co-IP

:   Co-immunoprecipitation

FBS

:   fetal bovine serum

GAPDH

:   glyceraldehyde 3-phosphate dehydrogenase

GSEA

:   gene set enrichment analysis

GTP

:   guanosine triphosphate

HRP

:   horseradish peroxidase

mRNA

:   messenger RNA

PBS

:   phosphate-buffered saline

PI

:   propidium iodide

RhoGAP

:   Rho GTPase-activating proteins

TCGA

:   The Cancer Genome Atlas
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